This company listing is no longer active
Mallinckrodt Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Información clave
-22.4%
Tasa de crecimiento de los beneficios
-21.5%
Tasa de crecimiento del BPA
| Crecimiento de la industria Pharmaceuticals | 6.0% |
| Tasa de crecimiento de los ingresos | -8.7% |
| Rentabilidad financiera | -358.7% |
| Margen neto | -32.7% |
| Última actualización de beneficios | 01 Apr 2022 |
Actualizaciones de resultados anteriores recientes
Recent updates
Desglose de ingresos y gastosBeta
Cómo gana y gasta dinero Mallinckrodt. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 01 Apr 22 | 2,142 | -699 | 592 | 176 |
| 31 Dec 21 | 2,209 | -723 | 571 | 205 |
| 24 Sep 21 | 2,294 | -674 | 615 | 231 |
| 25 Jun 21 | 2,486 | -213 | 653 | 250 |
| 26 Mar 21 | 2,106 | -1,057 | 689 | 280 |
| 25 Dec 20 | 2,213 | -970 | 769 | 291 |
| 25 Sep 20 | 2,336 | -1,976 | 788 | 307 |
| 26 Jun 20 | 2,381 | -2,169 | 791 | 345 |
| 27 Mar 20 | 3,038 | -1,219 | 825 | 342 |
| 27 Dec 19 | 3,163 | -1,007 | 828 | 349 |
| 27 Sep 19 | 3,193 | -3,565 | 847 | 368 |
| 28 Jun 19 | 3,249 | -3,449 | 874 | 351 |
| 29 Mar 19 | 3,251 | -3,446 | 881 | 364 |
| 28 Dec 18 | 3,216 | -3,622 | 878 | 361 |
| 28 Sep 18 | 3,842 | 1,841 | 906 | 393 |
| 29 Jun 18 | 3,642 | 1,780 | 968 | 354 |
| 30 Mar 18 | 3,417 | 1,795 | 967 | 314 |
| 29 Dec 17 | 3,222 | 1,771 | 977 | 277 |
| 29 Sep 17 | 2,591 | -150 | 1,066 | 210 |
| 30 Jun 17 | 2,877 | -93 | 1,075 | 231 |
| 31 Mar 17 | 3,144 | 65 | 1,084 | 254 |
| 30 Dec 16 | 3,400 | 208 | 1,078 | 267 |
| 30 Sep 16 | 3,381 | 489 | 929 | 261 |
| 24 Jun 16 | 3,686 | 522 | 1,021 | 213 |
| 25 Mar 16 | 3,593 | 381 | 1,036 | 197 |
| 25 Dec 15 | 3,494 | 335 | 1,062 | 196 |
| 25 Sep 15 | 2,923 | 235 | 897 | 203 |
| 26 Jun 15 | 2,795 | 38 | 847 | 211 |
Ingresos de calidad: MNKK.Q is currently unprofitable.
Margen de beneficios creciente: MNKK.Q is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: MNKK.Q is unprofitable, and losses have increased over the past 5 years at a rate of 22.4% per year.
Acelerando crecimiento: Unable to compare MNKK.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: MNKK.Q is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.9%).
Rentabilidad financiera
Alta ROE: MNKK.Q has a negative Return on Equity (-358.72%), as it is currently unprofitable.